ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

French health officials received dozens of reports of syringe pricks at a public festival, sparking fear about HIV and ...

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The Ghana HIV and AIDS Network (GHANET) is taking a proactive and strategic approach to combat the nation's HIV epidemic, focusing on a demographic often overlooked in health-seeking behaviours.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

In recent months, reports of rising HIV infections in Malaysia have once again made national headlines. The data paints a ...

Aurobindo Pharma will manufacture and supply these injectable HIV treatment across 133 countries, including several low and ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...